Online Resource 2 – Electronic Supplementary Material to:

Use and Outcomes of Cost-Effectiveness Analyses and Additional Considerations in Pharmaceutical Reimbursement in the Netherlands

Journal

PharmacoEconomics

Authors

Diederik Brokkelkamp[1]

Vivian Reckers-Droog[1]

Lonneke Timmers[1,2]

Pieter van Baal[1]

Affiliations

1. Erasmus School of Health Policy & Management (ESHPM), Erasmus University Rotterdam, Rotterdam, The Netherlands
2. National Health Care Institute (ZIN), Diemen, The Netherlands

Corresponding author

Diederik Brokkelkamp

Email: brokkelkamp@eshpm.eur.nl

Fig. S2 Flow of pharmaceutical-indications through ZIN's assessment steps to the subsets analysed in this study



Note. Of the 350 newly registered pharmaceutical-indications, 311 met the effectiveness criterion, 189 had added therapeutic value relative to the standard of care, and 86 underwent a CEA. The 65 CEAs with QALY gains at additional costs were included in the ICER distribution analysis. The 60 indications with a CEA and a negotiation recommendation were included in the analysis of additional considerations. Grey boxes indicate indications excluded at each filtering step; white boxes indicate the indications retained; blue boxes indicate the two analysis endpoints.